Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.7900
+0.0169 (2.19%)
At close: Oct 24, 2025, 4:00 PM EDT
0.7604
-0.0296 (-3.75%)
After-hours: Oct 24, 2025, 7:43 PM EDT
Xilio Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts that cover Xilio Therapeutics stock have a consensus rating of "Buy" and an average price target of $3.00, which forecasts a 279.75% increase in the stock price over the next year. The lowest target is $2.00 and the highest is $4.00.
Price Target: $3.00 (+279.75%)
Analyst Consensus: Buy
* Price targets were last updated on Aug 6, 2025.
Analyst Ratings
The average analyst rating for Xilio Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $2 | Buy | Initiates | $2 | +153.16% | Aug 6, 2025 |
| Raymond James | Raymond James | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +406.33% | Nov 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +786.08% | May 30, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +786.08% | May 11, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $10 | Buy | Maintains | $20 → $10 | +1,165.82% | Jan 27, 2023 |
Financial Forecast
Revenue This Year
39.31M
from 6.34M
Increased by 519.70%
Revenue Next Year
56.84M
from 39.31M
Increased by 44.57%
EPS This Year
-0.45
from -1.09
EPS Next Year
-0.32
from -0.45
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 47.9M | 85.8M | |||
| Avg | 39.3M | 56.8M | |||
| Low | 31.6M | 30.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 655.6% | 118.3% | |||
| Avg | 519.7% | 44.6% | |||
| Low | 397.4% | -23.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.46 | -0.19 | |
| Avg | -0.45 | -0.32 | |
| Low | -0.45 | -0.44 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.